Science 37 Holdings, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Science 37 Holdings, Inc. (NASDAQ: SNCE) operates as a clinical research technology company that provides a decentralized clinical trial platform enabling virtual and site-less studies for pharmaceutical, biotechnology, and medical device sponsors. The company's core offerings include the Science 37 Platform, which encompasses patient recruitment modules, teleconsent and remote monitoring tools, electronic clinical outcomes assessments (eCOA), and integrated wearable device data collection; the Clinical Trial Conductor for study management and real-time analytics; and services such as site-less trial design, regulatory consulting, and participant engagement through its proprietary Network of Sites. These solutions support a range of therapeutic areas including rare diseases, oncology, neurology, and cardiovascular conditions, serving biopharma sponsors, contract research organizations (CROs), and academic institutions primarily in North America and Europe. Founded in 2014 and headquartered in Research Triangle Park, North Carolina, the company has no major subsidiaries or parent relationships publicly noted. In recent developments within the last two years, Science 37 has pursued strategic partnerships with leading CROs like Parexel and ICON plc to expand decentralized trial capabilities, launched enhancements to its AI-driven patient matching technology in 2024, and completed a Series C funding extension raising over $75 million to fuel platform scaling and international growth into Asia-Pacific markets.
Science 37 Launches Dedicated Pediatrics Department to Expand Access to Specialized Clinical Research for Children and Families
Science 37 Appoints Kelly Johnston McKee as VP of Strategy & Transformation
Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research
Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC
Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials
CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial
Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance
Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment
eMed completes tender offer for all outstanding shares of Science 37
SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE
eMed commences tender offer for Science 37
SCIENCE 37 HOLDINGS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Science 37 Holdings, Inc. - SNCE
Shareholder Alert: Ademi LLP investigates whether Science 37 Holdings, Inc. has obtained a Fair Price in its transaction with eMed
SNCE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Science 37 Holdings, Inc. Is Fair to Shareholders
Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
Science 37 Receives Top Honors in Everest PEAK Matrix®
Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)